Antigenics, Inc. (ANTI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Antigenics, Inc. (ANTI) trades at $0.00001. Antigenics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in 1994, the company is based in Lexington, Massachusetts, and is engaged in innovative cancer treatment solutions. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ANTI: ANTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ANTI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ANTI: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Antigenics, Inc. (ANTI) Healthcare & Pipeline Overview
Antigenics, Inc. specializes in the discovery and development of innovative immunotherapies for cancer treatment, positioning itself within the clinical-stage biopharmaceutical sector as a pioneer in targeted therapies with a focus on enhancing patient outcomes.
What Is the Investment Thesis for ANTI?
Antigenics, Inc. presents a unique investment thesis centered around its innovative approach to immunotherapy in oncology. The company's clinical pipeline includes several promising candidates that target specific cancer types, with potential market sizes in the billions. As the global immunotherapy market is expected to grow significantly, driven by increasing cancer incidence and advancements in treatment modalities, Antigenics is well-positioned to capitalize on this trend. Key value drivers include successful clinical trial outcomes, strategic partnerships, and potential regulatory approvals, which could lead to significant revenue generation. Additionally, the absence of dividend payouts indicates a reinvestment strategy focused on growth. Investors should monitor the company's progress in clinical trials and its ability to secure funding for ongoing research as critical factors influencing its valuation.
Based on FMP financials and quantitative analysis
ANTI Key Highlights
Clinical-stage biopharmaceutical company focused on cancer immunotherapy.
- Founded in 1994, headquartered in Lexington, Massachusetts.
- No dividend yield, indicating a focus on reinvestment for growth.
- Beta of 1.00, reflecting market volatility alignment.
- Active development of multiple immunotherapeutic candidates.
Who Are ANTI's Competitors?
ANTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ANTI's Key Strengths?
Innovative focus on immunotherapy for cancer treatment.
- Experienced management team with a strong background in biotechnology.
- Proprietary technologies that differentiate product offerings.
What Are ANTI's Weaknesses?
Clinical-stage status may limit immediate revenue generation.
- Dependence on external funding for research and development.
- Limited product portfolio compared to larger competitors.
What Could Drive ANTI Stock Higher?
ANTI catalyst: Antigenics is expected to announce results from its ongoing clinical trials in Q3 2026, which could significantly impact its market position.
- The company is actively pursuing partnerships with research institutions to enhance its clinical capabilities and expedite product development.
- Antigenics is preparing for a potential regulatory submission for one of its leading immunotherapy candidates in late 2026.
What Are the Key Risks for ANTI?
The company faces risks associated with the clinical trial process, including the possibility of negative results that could hinder product development.
- Antigenics is subject to regulatory scrutiny, which could delay or prevent the approval of its therapies.
- Market competition may intensify, affecting the company's ability to capture market share in the oncology sector.
What Are the Growth Opportunities for ANTI?
- Growth opportunity 1: Antigenics is exploring expansion into new therapeutic areas within oncology, such as targeting rare cancers.
- Growth opportunity 2: The company is investing in partnerships with research institutions to enhance its clinical trial capabilities. Collaborations can accelerate the development of its immunotherapy candidates, potentially leading to earlier market entry and increased competitive advantage in a rapidly evolving market.
- Growth opportunity 3: Antigenics aims to leverage advancements in personalized medicine to tailor its therapies to specific patient populations. The personalized medicine market is projected to reach $2.5 trillion by 2026, presenting an opportunity for Antigenics to capture market share by offering targeted treatments that improve patient outcomes.
- Growth opportunity 4: The increasing global focus on cancer prevention and early detection is driving demand for innovative therapies. Antigenics can capitalize on this trend by developing immunotherapies that not only treat but also prevent cancer recurrence, tapping into a market that is expected to grow significantly in the coming years.
- Growth opportunity 5: With the rise of telemedicine and digital health solutions, Antigenics can explore integrating its therapies with digital platforms for patient monitoring and support. This approach could enhance patient engagement and adherence, ultimately improving treatment outcomes and expanding the company's market reach.
What Threats Does ANTI Face?
- Intense competition from established pharmaceutical companies.
- Regulatory challenges in obtaining drug approvals.
- Market volatility affecting funding and investment.
What Are ANTI's Competitive Advantages?
- Proprietary technologies that enhance the efficacy of immunotherapy.
- Strong focus on clinical development and regulatory expertise.
- Established relationships with research institutions and industry partners.
- Innovative approach to targeting specific cancer types, differentiating from competitors.
What Does ANTI Do?
Founded in 1994, Antigenics, Inc. is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts. The company is dedicated to discovering, manufacturing, and developing immunotherapies aimed at treating cancer. With a mission to improve the lives of cancer patients, Antigenics leverages its proprietary technologies to create targeted therapies that harness the body’s immune system to fight cancer cells. Over the years, the company has evolved from its initial focus on vaccine development to a broader portfolio of immunotherapeutic solutions. Antigenics is committed to advancing its clinical pipeline, which includes multiple candidates at various stages of development. The company operates in a competitive landscape characterized by rapid technological advancements and a growing demand for innovative cancer therapies. Its strategic focus on immunotherapy places it at the forefront of the biotechnology industry, where it seeks to address unmet medical needs in oncology. Antigenics collaborates with research institutions and industry partners to enhance its research capabilities and expedite the development of its therapeutic candidates, aiming for a significant impact on cancer treatment paradigms.
What Products and Services Does ANTI Offer?
- Develops immunotherapies specifically for cancer treatment.
- Conducts clinical trials to evaluate the efficacy and safety of its drug candidates.
- Manufactures biopharmaceutical products aimed at enhancing immune response against cancer.
- Collaborates with research institutions to advance cancer treatment solutions.
- Focuses on innovative technologies to target specific cancer types.
- Engages in regulatory processes to obtain approvals for its therapies.
How Does ANTI Make Money?
- Generates revenue through the development and commercialization of biopharmaceutical products.
- Collaborates with partners for research and development funding.
- Secures grants and investments to support clinical trials and product development.
- Focuses on long-term growth through reinvestment in research and innovation.
What Industry Does ANTI Operate In?
The biotechnology industry, particularly in the oncology sector, is experiencing rapid growth, with the global cancer immunotherapy market projected to reach approximately $150 billion by 2026. This growth is driven by increasing cancer prevalence and advancements in personalized medicine. Antigenics, Inc. operates within this dynamic environment, competing with other biotechnology firms that are also developing innovative cancer therapies. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, all vying for market share in a lucrative and expanding market. Antigenics' focus on immunotherapy positions it favorably in this competitive arena as demand for targeted cancer treatments rises.
Who Are ANTI's Key Customers?
- Healthcare providers and hospitals seeking advanced cancer treatment options.
- Patients diagnosed with cancer looking for innovative therapies.
- Research institutions collaborating on clinical development.
- Pharmaceutical partners interested in licensing or co-developing therapies.
Company Profile
Antigenics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Huntingdon Valley, US. The company is led by CEO Garo Armen. ANTI has traded publicly since 2018.
Key Financial Metrics
Return on equity for Antigenics, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ANTI trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
ANTI Financials
Bull Case vs Bear Case
Bull Case
- Innovative focus on immunotherapy for cancer treatment.
- Experienced management team with a strong background in biotechnology.
- Proprietary technologies that differentiate product offerings.
- Upcoming: Antigenics is expected to announce results from its ongoing clinical trials in Q3 2026, which could significantly impact its market position.
Bear Case
- Clinical-stage status may limit immediate revenue generation.
- Dependence on external funding for research and development.
- Limited product portfolio compared to larger competitors.
- Potential: The company faces risks associated with the clinical trial process, including the possibility of negative results that could hinder product development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ANTI Latest News
No recent news available for ANTI.
ANTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANTI.
Price Targets
Wall Street price target analysis for ANTI.
ANTI MoonshotScore
What does this score mean?
The MoonshotScore rates ANTI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
ANTI OTC Market Information
ANTI trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About ANTI (Healthcare)
What does Antigenics, Inc. do?
Antigenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapies for cancer treatment. The company aims to harness the body's immune system to combat cancer cells, offering innovative solutions in the oncology market. Through its clinical trials, Antigenics seeks to evaluate the safety and efficacy of its drug candidates, contributing to advancements in cancer therapy.
What is Antigenics, Inc.'s drug pipeline status?
Antigenics, Inc. currently has several candidates in its clinical pipeline, focusing on various cancer types. The company is engaged in multiple phases of clinical trials, with key therapeutic areas that include solid tumors and hematologic malignancies. Upcoming catalysts include the anticipated results from ongoing trials, which could significantly influence the company's future direction and market opportunities.
What are the key growth opportunities for ANTI in healthcare?
Antigenics, Inc. has several growth opportunities, including expansion into new therapeutic areas within oncology and partnerships with research institutions to enhance its clinical trial capabilities. The company is also exploring advancements in personalized medicine, which is projected to significantly grow in the coming years. Additionally, the rising demand for innovative cancer therapies presents a favorable environment for Antigenics to capture market share.
What are the key factors to evaluate for ANTI?
Evaluate ANTI on fundamentals, analyst consensus, and risk factors. Antigenics, Inc. presents a unique investment thesis centered around its innovative approach to immunotherapy in oncology. Not financial advice.
How frequently does ANTI data refresh on this page?
ANTI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ANTI's recent stock price performance?
Antigenics, Inc. (ANTI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on immunotherapy for cancer treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANTI overvalued or undervalued right now?
Antigenics, Inc. (ANTI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ANTI before investing?
Before investing in Antigenics, Inc. (ANTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on current market conditions and company disclosures as of March 2026.